ASPREE Chief Investigator in Tasmania, Professor Mark Nelson gives a great interview on ABC Radio National’s Health Report about aspirin and primary prevention. He discusses the JPPP (Japanese Primary Prevention Projection) and the ASPREE trial. To listen to the interview click here. Read the transcript here.
PRESS RELEASE: Melbourne, 20 October 2014: The use of aspirin to prevent cancer will be discussed by experts at a symposium in Melbourne today. Leading healthcare professionals will discuss the scientific evidence for and against the use of aspirin for the chemoprevention of cancer. With the rising importance of disease prevention, researchers are looking at…Details
Crossing the border into SA this week. With around half of ASPREE participants living in regional and rural areas, the Biobank team designed a mobile laboratory called an ASPREE ‘Biobus’. We now have two in Victoria and one in Tasmania. Each vehicle is fully equipped to collect, process and store samples over several days at a…Details
Hearing loss associated with ageing, experienced by two-thirds of people over the age of 70 years, can have a profound effect on a person’s independence and quality of life. There is no known single cause and no known cure for this type of hearing loss. The ASPREE-Hearing (Aspirin in HEAring Retinal vessels, Inflammatory markers, Neurocognition…Details
A large scientific review which revealed that aspirin protected people aged 50-65 against gastrointestinal cancer, was unable to determine cancer benefits for those aged over 70. International researchers, who analysed around 200 papers, explained there was ‘uncertainty’ about the balance of benefits versus the risk of daily low-dose aspirin in older people. “For example the…Details
ASPREE Principal Investigator in Australia, Professor John McNeil discussed what the findings of ASPREE may mean to future health care in this week’s GP publication ‘Medical Observer’. He wrote: “Currently, it is not known if low-grade inflammation is a cause or consequence of the diseases of ageing. If ASPREE shows lower incidence of disease and disability among those with reduced inflammatory…Details
PRESS RELEASE Wollongong locals to participate in Australia’s largest primary prevention Aspirin Trial Wollongong, October 3, 2013 – The ASPREE (ASPirin in Reducing Events in the Elderly) study – the largest primary prevention aspirin study ever undertaken in older people – is calling on local residents from Wollongong and surrounding regions to participate in the study.…Details
ASPREE has now enrolled over 12,500 participants in Australia, our original target when the trial was launched in 2010. To our wonderful older members of the community participating in ASPREE and to their supportive family and friends and GPs, thank you. Congratulations also to our hardworking team.
A leading Australian medical researcher recommends that healthy people of all ages should consult their GP prior to commencing aspirin for disease prevention. Professor Mark Nelson (pictured left) was commenting after new research suggested that aspirin may reduce the risk of women developing colon cancer. He said the study, which found that women who took…Details
Medical Oncologist Dr Andrew Haydon, who oversees cancer aspects of a world-first aspirin trial, ASPREE, said that the recent association between aspirin and a reduced risk of developing melanoma was a call for closer investigation of aspirin’s anti-tumour effect. Melanoma is the most deadly form of skin cancer and is on the rise in Australia.…Details